US6152141A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for delivery of therapeutic agents to the heart
Assignee: Edwards Lifesciences LLC
•
Filing: 1997-12-08
•
Granted: 2000-11-28
•
Expires: 2017-12-08
Abstract
Abstract A method for delivering a therapeutic agent directly to the heart employing minimally invasive techniques and concepts. In particular, the delivery of vascular endothelial growth factors (VEGF) is performed endovascularly or endoscopically to a region of a patient's heart treated with transmyocardial revascularization (TMR). A system is provided for inducing cardioplegic arrest. An aortic occlusion device has an inflatable balloon which occludes the ascending aorta when inflated. Cardioplegic fluid may be infused through a lumen of the aortic occlusion device to stop the heart while the patient's circulatory system is supported on cardiopulmonary bypass. A side-firing fiberoptic laser is introduced through the aortic occlusion device in the endovascular technique to perform TMR. Subsequently, a therapeutic agent delivery catheter is directed into one of the coronary arteries to deliver and dissipate the VEGF into the surrounding vascular plexus to promote angiogenesis stimulation. Alternatively, a therapeutic agent delivery material saturated or coated with VEGF could be sutured to the epicardial surface of the heart, using thoracoscopic techniques, for timed release delivery of the agent to the TMR treated site.
Inventors
- 👤 John H. Stevens
- 👤 Richard B. Brewer
- 👤 Daniel C. Rosenman
- 👤 Hanson S. Gifford, III
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:42
CPC Classifications
A; A61; A61M; A61M25/00; A61M25/10; A61M25/104; A61B; A61B18/00; A61B18/18; A61B18/20; A61B18/22; A61B18/24; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2427; A61M1/00; A61M1/36; A61M1/3621; A61M1/3653; A61M1/3655; A61M1/3659; A61M25/0021; A61M25/0041; A61B17/00; A61B17/00234; A61B2017/00238; A61B2017/00243; A61B2017/00247; A61B2018/00053; A61B2018/00214; A61B2018/0022; A61B2018/00232; A61B2018/0025; A61B2018/00261; A61B2018/00315; A61B2018/00345; A61B2018/00351; A61B2018/00392; A61M25/0023; A61M25/0026; A61M2025/0034; A61M2025/004; A61M25/0043; A61M2025/0057; A61M25/0067; A61M25/0074; A61M25/0075; A61M2025/0076; A61M2025/0078; A61M25/01; A61M25/02; A61M2025/028; A61M2025/1043; A61M2025/1047; A61M2025/1077; A61M2205/00; A61M2205/11; A61M2205/36; A61M2205/366; A61M2210/00; A61M2210/12; A61M2210/125; A61M25/0068; A61M25/007; A61M25/0105; A61M25/0125; A61M25/1002
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
112 words
A method for delivering a therapeutic agent to the heart of a patient comprising the steps of: placing an aortic occlusion device in a location within a patient's ascending aorta, the aortic occlusion device having an occluding member and a lumen extending therethrough having an outlet in fluid communication with the patient's ascending aorta; expanding said occluding member within the patient's ascending aorta to occlude the ascending aorta; infusing a cardioplegic agent into a coronary vasculature of said patient to arrest the patient's heart; maintaining circulation of oxygenated blood in the patient while the patient's heart is arrested; and delivering a therapeutic agent into the coronary vasculature through the aortic occlusion device.
Claim 2
Independent Claim
112 words
A method for delivering a therapeutic agent to the heart of a patient comprising the steps of: placing an aortic occlusion device in a location within a patient's ascending aorta, the aortic occlusion device having an occluding member and a lumen extending therethrough having an outlet in fluid communication with the patient's ascending aorta; expanding said occluding member within the patient's ascending aorta to occlude the ascending aorta; infusing a cardioplegic agent into a coronary vasculature of said patient to arrest the patient's heart; maintaining circulation of oxygenated blood in the patient while the patient's heart is arrested; and delivering a therapeutic agent into the coronary vasculature through the aortic occlusion device.
Claim 3
Dependent Claim
36 words
The method of claim 1 further comprising the step of: advancing a laser catheter through the aortic occlusion device; positioning the laser catheter in the patient's heart; and performing a transmyocardial revascularization with the laser catheter.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein, said agent includes vascular endothelial growth factors.
Claim 5
Dependent Claim
18 words
The method of claim 1 further comprising the step of: delivering a stent through the aortic occlusion device.
Claim 6
Dependent Claim
18 words
The method of claim 4 wherein, the stent includes vascular endothelial growth factors and a fibrin based glue.
Claim 7
Dependent Claim
72 words
The method of claim 1 wherein, said delivering step is performed by: passing a distal end of a needle sheath through said lumen of said elongated aortic catheter; passing a needle of an injection catheter through a lumen of said needle sheath; and piercing the coronary artery wall with the needle upon advancement thereof through an opening in the needle sheath into the coronary artery; and injecting the agent through the needle.
Claim 8
Dependent Claim
37 words
The method of claim 1 further comprising the step of: occluding the patient's superior vena cava and inferior vena cava to substantially isolate the delivery of the agent to the patient's heart and prevent systemic circulation thereof.
Claim 9
Dependent Claim
32 words
The method of claim 1 further comprising the step of: withdrawing the agent from the coronary vasculature through a coronary sinus catheter; occluding the patient's coronary sinus with the coronary sinus catheter.
Claim 10
Dependent Claim
90 words
The method of claim 1 wherein said delivering step is performed by: passing a distal end of a catheter through said lumen of said aortic occlusion device, said catheter having an expandable member at the distal end of thereof, expanding the expandable member to radially expand a flexible infusion array, coupled therearound, against the coronary artery interior wall; and infusing the agent into the coronary artery interior wall through a plurality of orifices in the infusion array while the infusion array remains in contact with the coronary artery interior wall.
References Cited (Backward Citations)
US35352A
Cited
EP0218275A1
Cited
US5575815A
Cited
US5272263A
Cited
US5298487A
Cited
US5332671A
Cited
US5580722A
Cited
US5194596A
Cited
US5219739A
Cited
US5312344A
Cited
US5370685A
Cited
US5558644A
Cited
US5885238A
Cited
US5545214A
Cited
US5702368A
Cited
US5584803A
Cited
US5499996A
Cited
US5556412A
Cited
US5522838A
Cited
US5330498A
Cited
US5549674A
Cited
US5586982A
Cited
US5318957A
Cited
US5354279A
Cited
US5336178A
Cited
US5433700A
Cited
USRE35352E
Cited
US5718725A
Cited
US5336518A
Cited
US5279565A
Cited
US5536251A
Cited
US5682906A
Cited
US5569274A
Cited
US5571215A
Cited
US5425705A
Cited
US5452733A
Cited
US5567417A
Cited
US5505701A
Cited
US5533516A
Cited
US5501698A
Cited
US5419777A
Cited
US5458574A
Cited
US5588962A
Cited
US5599306A
Cited
US5478309A
Cited
US5634895A
Cited
US5695457A
Cited
US5591197A
Cited
US5626607A
Cited
US5618307A
Cited
WO1997047253A1
Cited
WO1998005307A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-11-28 | 2004-05-29 | 2004-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-11-28 | 2008-05-29 | 2008-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-11-28 | 2012-05-29 | 2012-11-28 | $7700.00 | Window Closed / Lapsed |